UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
__________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 28, 2007
AngioDynamics, Inc.
(Exact Name of Registrant as Specified in Charter)
|
Delaware |
000-50761 |
11-3146460 |
|
|
|
|
|
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
|
603 Queensbury Avenue, Queensbury, New York |
12804 |
|
|
|
|
(Address of Principal Executive Offices) |
(Zip Code) |
(518) 798-1215
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
o |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
o |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
o |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b)) |
|
o |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4 (c)) |
Item 8.01 – Other Events.
On March 28, 2007, the jury in the previously disclosed lawsuit filed on January 6, 2004 by Diomed, Inc. (“Diomed”) against AngioDynamics, Inc. (the “Company”) entitled Diomed, Inc. v. AngioDynamics, Inc., civil action no. 04 10019 RGS in the U.S. District Court for the District of Massachusetts, returned a verdict in favor of Diomed. Diomed’s complaint alleged that the Company infringed on Diomed’s U.S. patent no. 6,398,777 by selling a kit for the treatment of varicose veins (now called the “VenaCure Procedure Kit”) and two diode laser systems: the Precision 980 Laser and the Precision 810 Laser, and by conducting a training program for physicians in the use of the Company’s VenaCure Procedure Kit. The Company intends to set aside or appeal the verdict.
A copy of the press release issued by the Company on March 28, 2007, announcing its intention to set aside or appeal the verdict is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01 – Financial Statements and Exhibits.
|
(d) |
Exhibits. |
|
Exhibit No. |
|
Description
|
|
99.1 |
|
Press Release dated March 28, 2007. |
|
|
|
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
ANGIODYNAMICS, INC. | |
|
|
(Registrant) | |
|
|
|
|
|
|
|
|
|
Date: March 30, 2007 |
By: |
/s/ Joseph G. Gerardi |
|
|
|
Joseph G. Gerardi |
|
|
|
Vice President, Chief Financial Officer |
|
|
|
and Treasurer |
EXHIBIT INDEX
|
Exhibit No. |
|
Description
|
|
|
|
|
|
99.1 |
|
Press Release dated March 28, 2007. |
|
|
|
|